NuCana
Clinical-stage biopharmaceutical company developing next-generation cancer medicines using its proprietary ProTide technology to deliver nucleotide analogs more effectively to cancer cells.
Website
https://www.nucana.comLocation
Edinburgh, United Kingdom
Founded
2008
Investors
1
Categories
oncology, cancer-therapeutics, biotech, prodrug-technology
Notes
NuCana is a clinical-stage biopharmaceutical company developing transformative cancer medicines using its proprietary ProTide technology. ProTide chemistry enables the efficient delivery of nucleotide analogs directly into cancer cells, overcoming key resistance mechanisms that limit the efficacy of existing nucleoside analogs.
The company has multiple clinical programs targeting various solid tumors, including biliary tract cancer and other difficult-to-treat cancers.
Team
- Hugh Griffith - Founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/hughgriffith
- Stephen Shochat - Co-founder & Chief Scientific Officer
Additional Research Findings
- Founded in 2008 in Edinburgh, UK
- Listed on NASDAQ (ticker: NCNA)
- Proprietary ProTide technology for enhanced nucleotide delivery
- Lead candidate: NUC-3373 (prodrug of 5-FU metabolite)
- Focus on overcoming resistance to existing cancer drugs
- ProTide technology licensed from Cardiff University
- Multiple clinical trials ongoing in various solid tumors
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |